A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines

Allergan

Status: Withdrawn

Conditions: Chronic Migraine, Headache

Treatments: Biological: OnabotulinumtoxinA

Study type: Observational

Funder types: Industry

Identifiers

NCT01749423

GMA-BTX-CM-12-518

Details and patient eligibility

About

This study will evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in patients with Chronic Migraine.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of chronic migraines
• 15 or more headache days over a 30 day period
• A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between 155 and 195 units

Exclusion criteria

• Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Trial design

0 participants in 1 patient group

All participants

Description:

Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.

Treatment:

Biological: OnabotulinumtoxinA